Core Insights - Tempus AI, Inc. has achieved a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025 [1] - The company signed data agreements with over 70 customers in 2025, including major pharmaceutical companies [1] Company Overview - Tempus AI, Inc. is a technology company focused on advancing precision medicine through the adoption of artificial intelligence [1] - The company operates in the healthcare technology sector, specifically targeting the pharmaceutical industry [1] Customer Engagement - The customer base includes both large and mid-sized pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, and Boehringer Ingelheim [1] - The agreements signed in 2025 reflect a strong demand for Tempus's AI-driven solutions in the pharmaceutical sector [1]

Core Insights - Adding dividend stocks to a portfolio can provide steady income and mitigate losses during market downturns, but thorough research is essential to ensure sustainability and alignment with growth goals and risk preferences [1] - Companies with a history of consistent and increasing dividend payments signal stability and good management, while focusing solely on dividend yield can be misleading [2][3] Company Overview: VICI Properties - VICI Properties (NYSE: VICI) is a real estate investment trust (REIT) specializing in experiential real estate, owning a portfolio of 93 assets, including major destinations on the Las Vegas Strip like Caesars Palace and MGM Grand [5] - Established in 2017 as a spinoff from Caesars Entertainment, VICI has maintained a reliable dividend payout, increasing its annual dividend for seven consecutive years since its IPO, with a current annual dividend of approximately $1.80 per share and a strong yield of around 6.3% [6] - Utilizing a triple-net lease model, VICI separates property ownership from operations, ensuring tenants cover all property-related expenses, and maintains a 100% occupancy rate with long-term leases that include rent escalators linked to the Consumer Price Index (CPI) [7]

Core Viewpoint - Investing in dividend-paying stocks is highlighted as a beneficial strategy for generating a growing income stream by 2026, with specific recommendations for top dividend investments [1]. Realty Income - Realty Income aims to provide reliable monthly dividend income that increases over time, having raised its dividend 133 times since its public listing in 1994, including 113 consecutive quarters [3]. - The current monthly dividend yield is 5.7%, significantly higher than the S&P 500 average of around 1.2%, translating to approximately $4.75 monthly income for every $1,000 invested, or $57 annually [4]. - Realty Income maintains a diversified real estate portfolio, generating stable rental income through long-term net leases, and pays out about 75% of its cash flow in dividends, retaining the rest for further investments [6]. Brookfield Infrastructure - Brookfield Infrastructure is a global leader in infrastructure, owning utility, energy midstream, transportation, and data assets, which provide stable cash flow supported by long-term contracts [7]. - The company has consistently increased its dividend since 2008, with a current yield of 3.8% and a target growth rate of 5% to 9% annually [9]. - Brookfield has $7.8 billion in organic expansion projects planned over the next two to three years, alongside $1.5 billion in new investments, positioning it for over 10% annual growth in funds from operations per share [10]. Schwab U.S. Dividend Equity ETF - The Schwab U.S. Dividend Equity ETF is recognized as a top dividend ETF, holding 100 high-yielding dividend stocks selected based on quality characteristics [11]. - The ETF currently offers a dividend yield of 3.7%, with its holdings having increased dividends by an average of over 8% annually over the past five years [12]. - Notable holdings include Bristol Myers Squibb, which has a 1.6% recent dividend increase, extending its growth streak to 17 years, and has paid dividends for 94 consecutive years [13].

Group 1: Market Volatility and Reactions - The year 2025 has been marked by significant market volatility, heavily influenced by presidential announcements, particularly from Donald Trump, leading to rapid fluctuations in market values [1] - Following the announcement of a 10% universal tariff on all US imports, the S&P 500 dropped over 10%, erasing approximately $5 trillion from global markets [5] - A subsequent 90-day pause on new reciprocal tariffs resulted in a market rebound, with the S&P 500 surging 9.52% [5][6] Group 2: Trump Media & Technology Group (DJT) - Trump Media & Technology Group (DJT) saw its stock surge 13.03% after announcing a merger with TAE Technologies, a nuclear fusion company, indicating a pivot from social media to energy [3] - DJT stock closed at $16.80 before the merger announcement, marking a significant rise, and trading volume reached 99.5 million shares, 1,265% above its three-month average [3] - Despite the recent surge, DJT stock remains down 58% over the past year, highlighting ongoing volatility [3] Group 3: Pharmaceutical Industry Developments - Trump announced new drug pricing deals with nine major pharmaceutical companies, including Merck and Pfizer, aimed at lowering Medicaid drug prices [7] - Merck committed to approximately 70% discounts on diabetes treatments, while Pfizer agreed to significant price cuts and a $70 billion investment in U.S. research [8] - These deals included a three-year exemption from Section 232 tariffs for the pharmaceutical companies, creating a win-win scenario for both the industry and consumers [8] Group 4: Nvidia and Geopolitical Dynamics - The U.S. government approved the export of Nvidia's H200 chips to select Chinese customers, with a 25% revenue cut going to the government, reflecting complex geopolitical dynamics [9][10] - Nvidia's stock saw a positive reaction, closing at $176.29 and rising to $183.40 following the announcement, despite ongoing investor caution regarding China exposure [10] Group 5: Economic Overview - Despite stock market gains of 13% to 20% year-to-date, public sentiment regarding the economy remains low, with 70% of Americans describing it as "poor" [11] - Trump's approval rating on economic performance has dropped to between 31-39%, indicating a disconnect between market performance and public perception [11] - The Federal Open Market Committee has been cutting interest rates to stimulate the economy, reflecting concerns about rising prices and unemployment [12]

Group 1: Drug Pricing Agreements - President Trump announced "historic" drug pricing agreements with nine major pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, aimed at reducing prices for Medicaid and direct-to-consumer sales through TrumpRx.gov [2][3] - The agreements are intended to align U.S. drug costs with the lowest prices paid by other developed nations, a concept known as "most-favored-nation" pricing [2] Group 2: Market Reactions to Drug Pricing - Despite the price cuts, pharmaceutical stocks saw gains, with GSK rising 1%, Merck gaining 1%, and Gilead Sciences surging approximately 3% [3] - The rally in stock prices is attributed to tariff exemptions secured by these companies in exchange for their pricing agreements, which alleviated potential tariff burdens [3][4] Group 3: Tariff Impacts - The U.S. effective tariff rate increased from 2.4% to 16.8%, the highest since 1935, contradicting claims that tariffs would reduce costs [5] - Market reactions to tariff announcements have been volatile, with significant drops in major indices following threats of tariff increases, such as a 2.7% decline in the S&P 500 on October 11, 2025 [6][8] Group 4: Economic Analysis of Tariffs - Analysts from Goldman Sachs warned that increased tariffs could significantly impact growth, estimating a reduction of nearly 0.7 percentage points from China's growth in 2025 [8] - The Tax Foundation labeled Trump's tariffs as the "largest tax hike since 1993," estimating an average increase of $1,100 per U.S. household in 2025 [8] Group 5: Warrior Dividend Announcement - President Trump announced a "$1,776 'warrior dividend'" for U.S. military personnel, funded by tariffs, totaling an estimated $2.6 billion [9][10] - Reports clarified that these payments were not new funds from tariffs but repurposed from existing military housing supplements, indicating a rebranding of existing funds rather than a new financial initiative [10][11] Group 6: Overall Economic Environment - The unpredictable nature of Trump's economic policies has led to erratic market behavior, with investors needing to navigate through rhetoric and actual economic impacts [12] - The combination of drug pricing agreements, tariff threats, and the warrior dividend illustrates the complex interplay of policy and market reactions in the current economic landscape [12]

Core Viewpoint - The Schwab U.S. Dividend Equity ETF (SCHD) is highlighted as an ideal investment for income-focused investors, offering a combination of high yield and potential capital gains through a diversified portfolio of stocks [2][4]. Group 1: ETF Overview - The Schwab U.S. Dividend Equity ETF has been established for 14 years and is managed by Charles Schwab, boasting over $71 billion in net assets, making it one of the largest high-yield ETFs [4]. - The ETF has a low expense ratio of 0.06%, ensuring that investors are not overpaying for its benefits [5]. - It pays quarterly dividends with a 30-day SEC yield of 3.8%, which is close to the 10-year Treasury rate of 4.2%, providing a competitive passive income option [6]. Group 2: Investment Strategy - The ETF targets large-cap, high-yield stocks, with approximately 90% of its investments in companies with market capitalizations exceeding $15 billion, appealing to investors seeking diversification [8]. - Over half of the ETF's investments are concentrated in three sectors: energy, consumer staples, and healthcare, which are known for prioritizing dividend growth [9]. Group 3: Sector and Holdings - Key energy holdings include major companies like Chevron, ConocoPhillips, and EOG Resources, which help manage risk across the oil and gas value chain [10]. - The top healthcare holdings, such as Merck and Amgen, offer high yields and favorable valuations, while leading consumer staples like PepsiCo and Coca-Cola have consistently raised dividends for over 50 years, earning the title of Dividend Kings [11]. Group 4: Performance and Value - Since its inception in October 2011, the Schwab U.S. Dividend Equity ETF has more than tripled in value, demonstrating its potential for capital gains alongside dividend income [13]. - The ETF is positioned as a foundational holding for value-focused portfolios or as a means to balance portfolios that have become overly concentrated in growth stocks [12].

Group 1: Drug Price Cuts and Pharmaceutical Stocks - President Trump announced significant drug price cuts in collaboration with nine major pharmaceutical companies, aiming to align U.S. drug costs with those in other developed nations [2] - Despite the announcement of price cuts, shares of involved drugmakers like GSK, Merck, Amgen, Novartis, Sanofi, and Roche rose by approximately 1% to 3%, as the deals removed the immediate threat of punitive tariffs for three years [3] - Analysts noted that the deals serve more as a public relations strategy rather than a substantial change in company economics, with Medicaid already benefiting from significant discounts [4] Group 2: Market Reactions to Health Insurers - Major health insurers such as Cigna, CVS Health, Elevance Health, and UnitedHealth Group experienced an initial dip of about 1% following Trump's comments but quickly recovered, indicating a market accustomed to Trump's policy announcements [5] Group 3: Merger of Trump Media & Technology Group and TAE Technologies - Trump Media & Technology Group announced a merger with TAE Technologies, valuing the combined entity at $6 billion, which led to a 42% surge in DJT shares, closing at $14.86 [7] - The merger has drawn mixed reactions, with some analysts viewing it as a significant move towards creating a public nuclear fusion company, while others criticized it as a questionable venture [9] Group 4: Tariff Threats and Market Volatility - Throughout 2025, Trump's threats and impositions of tariffs, particularly against China, have caused significant market volatility, including a $5 trillion market wipeout following an April tariff announcement [11] - The S&P 500 and Nasdaq Composite experienced substantial declines during tariff threats, but the market has shown resilience, often recovering to new highs [12] Group 5: Overall Market Environment - As 2025 concludes, the financial markets continue to be influenced by Trump's unpredictable policies, creating a landscape where traditional analysis is often overshadowed by political developments [13]

Industry Overview - The global oncology market is evolving significantly due to rising cancer incidence and rapid scientific advancements, with the American Cancer Society estimating approximately 2.04 million new cancer diagnoses and over 618,000 cancer-related deaths in the U.S. by 2025 [2] - Aging populations and lifestyle-related risk factors are contributing to higher cancer prevalence, leading to sustained growth in healthcare spending on oncology [2] Innovation in Cancer Care - Breakthroughs in immunotherapies, targeted treatments, and personalized vaccines are expanding therapeutic options beyond conventional chemotherapy and radiation [3] - Immune-based strategies, including checkpoint inhibitors and CAR-T therapies, are harnessing the body's immune system to target tumors, while targeted therapies focus on specific genetic alterations [3] - Emerging technologies like genomic sequencing, AI, and machine learning are enhancing biomarker discovery and supporting earlier diagnosis, improving survival rates and quality of life across several cancer types [4] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, Johnson & Johnson (J&J), Pfizer, AbbVie, Merck, Bristol Myers Squibb, and Eli Lilly, are investing aggressively in oncology portfolios with new therapies such as antibody-drug conjugates and bispecific antibodies [5] - Smaller biotech firms are also crucial in driving innovation through partnerships, licensing agreements, and acquisitions [5] Market Dynamics - Oncology is considered one of the most durable and attractive segments within the global healthcare sector for long-term investors, supported by ongoing innovation and favorable reimbursement dynamics [6] Company Focus: Johnson & Johnson - J&J's oncology segment currently accounts for approximately 27% of its total revenues, with oncology sales rising 20.6% to $18.52 billion in the first nine months, driven by key products like Darzalex and Erleada [9] - J&J's oncology pipeline has gained momentum with promising developments in colorectal and head and neck cancers, and the company expects its oncology sales to reach $50 billion by the end of the decade [10][12] - J&J is also enhancing its oncology pipeline through M&A, including a recent agreement to acquire Halda Therapeutics [11] Company Focus: ImmunityBio - ImmunityBio's lead drug, Anktiva, was approved for treating BCG-unresponsive non-muscle invasive bladder cancer, generating $74.7 million in sales with a 467% increase in volume [13] - The drug is under review in the EU, and ImmunityBio is evaluating Anktiva for expanded use in other cancer indications [15] Company Focus: Foghorn Therapeutics - Foghorn Therapeutics is developing precision therapies targeting genetically driven vulnerabilities, with a collaboration with Lilly to co-develop its selective SMARCA2 oncology program [17] - Foghorn's lead candidate, FHD-909, is advancing in a phase I study for SMARCA4-mutated cancers, with initial data expected in 2026 [17][18]

Financial Data and Key Metrics Changes - Revenue for the quarter was $18.7 billion, reflecting a 5% growth in local currency and a 6% increase in U.S. dollars, at the top of the guided range [17][19] - Adjusted operating margin expanded by 30 basis points year over year to 17% [18][22] - Adjusted EPS grew by 10% year over year to $3.94 [18][22] - Free cash flow for the quarter was $1.5 billion, with a cash balance of $9.6 billion [23] Business Line Data and Key Metrics Changes - New bookings totaled $20.9 billion, representing a 12% growth in U.S. dollars and a 10% growth in local currency [18][19] - Consulting revenues were $9.4 billion, growing 4% in U.S. dollars and 3% in local currency [19] - Managed services revenues reached $9.3 billion, with an 8% increase in U.S. dollars and 7% in local currency [19] Market Data and Key Metrics Changes - In the Americas, revenue grew 4% in local currency, with a 6% growth excluding federal business impacts [20] - EMEA saw a 4% growth in local currency, driven by banking and capital markets [20] - Asia-Pacific revenue grew 9% in local currency, led by banking and capital markets [21] Company Strategy and Development Direction - The company focuses on being a reinvention partner for clients, emphasizing large-scale transformational programs [25] - Advanced AI is increasingly embedded in solutions, with a significant focus on data management and modernization [26][36] - The partnership strategy is crucial, with 60% of revenue coming from top ecosystem partners, which is expected to continue driving growth [12][14] Management's Comments on Operating Environment and Future Outlook - Management noted that clients are prioritizing strategic transformational programs despite a lack of change in discretionary spending [72] - The demand for advanced AI is growing, with expectations for significant market expansion in the coming years [34] - The company anticipates revenue growth of 2-5% in local currency for fiscal 2026, with a focus on maintaining strong cash returns to shareholders [39][40] Other Important Information - The company recorded $308 million in business optimization costs, impacting operating margin and EPS [21] - The company plans to invest approximately $3 billion in acquisitions for fiscal 2026 [39] Q&A Session Questions and Answers Question: Shift in consulting industry's role in AI - Management acknowledged a shift in perception, emphasizing that enterprise AI adoption requires foundational work around data and processes [43][44] Question: Timing for AI partnerships to impact revenue - Management indicated that the impact of AI partnerships on revenue is tied to enterprise adoption, which is expected to evolve over time [51][52] Question: Sustainability of revenue growth outpacing headcount growth - Management confirmed that revenue per person grew 7%, driven by talent rotation, and expects this trend to moderate [56][57] Question: Discretionary spending outlook - Management stated that they are not waiting for discretionary spending to return, focusing instead on delivering results through large transformational deals [72] Question: Fixed-price work growth potential - Management expressed confidence in the competitive advantage of fixed-price deals, noting that they provide clients with certainty in outcomes [74][75]

Core Insights - Harbour BioMed has entered a multi-year global strategic collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies [1][2] - The agreement includes potential payments totaling $90 million and up to $1.035 billion in development and commercial milestones, along with tiered royalties [2] Company Overview - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology [4] - The company aims to build a robust portfolio through internal R&D, collaborations, and selective acquisitions [4] Technology and Innovation - The proprietary Harbour Mice technology platform generates fully human monoclonal antibodies in various formats, enhancing the therapeutic potential of biologics [5] - The HCAb-based immune cell engagers (HBICE) technology allows for tumor-killing effects that traditional therapies cannot achieve, making the antibody discovery engine unique and efficient [5] Strategic Collaboration - The collaboration with Bristol Myers Squibb is expected to leverage Harbour BioMed's technology and development capabilities, particularly in conducting early clinical trials in China [3]